Nedaplatin
Based on 1 publication(s) in Google Scholar
Nedaplatin (NSC 375101D) is a derivative of cisplatin and DNA damage agent.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 95734-82-0
- Formula: C2H8N2O3Pt
- Molecular Weight:303.18
-
Storage:Powder -20°C, 3 years , 4°C, 2 years
* The compound is unstable in solutions, freshly prepared is recommended.
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Nedaplatin
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
Nedaplatin (NSC 375101D, NDP) is a derivative of cisplatin which produced less nausea & vomiting and nephrotoxicity. the effect of NDP on the 7-ethyl-1-hydroxy-CPT (the active form of CPT-11)-induced inhibitory effect on DNA topoisomerase I was examined. The topoisomerase I-inhibitory effect of 7-ethyl-1-hydroxy-CPT was enhanced 10-fold in the presence of Nedaplatin (NSC 375101D, NDP) at microgram/milliliter concentrations[1]. Nedaplatin (NSC 375101D, NDP) was developed as a second generation platinum complex. Because it has greater antitumour activity and lower nephrotoxicity than cisplatin (CDDP). At the high-dose of Nedaplatin (NSC 375101D, NDP) in FN therapy, a reduction of tumour size and long-term tumour-free survival were frequently observed. The survival effect of the combinations of Nedaplatin (NSC 375101D, NDP) with 5-FU was superior to those of the combination of CDDP with 5-FU. In conclusion, the sequence-dependent antitumour efficacy and toxicity of the combination of NDP or CDDP with 5-FU was demonstrated in this study, and FN therapy appeared to be the most efficient regimen as a clinical therapy[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 95734-82-0
-
Appearance Solid
-
Molecular Weight 303.18
-
Formula C2H8N2O3Pt
-
Color Light yellow to yellow
-
SMILES
O=C1C[O-][Pt+2](N)(N)[O-]1
-
Synonyms
NSC 375101D
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years * The compound is unstable in solutions, freshly prepared is recommended.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Vet Parasitol
Inhibiting thioredoxin glutathione reductase is a promising approach to controlling Cryptocaryon irritans infection in fish. [Abstract]2023 Aug:320:109972. PMID: 37385103
Solvent & Solubility
H2O : 8.33 mg/mL (27.48 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Nedaplatin's activity)
DMF : < 1 mg/mL (insoluble; DMSO can inactivate Nedaplatin's activity)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 7.14 mg/mL (23.55 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (585 KB)
- English - EN (585 KB)
- Français - FR (585 KB)
- Deutsch - DE (585 KB)
- Norwegian - NO (585 KB)
- Español - ES (585 KB)
- Swedish - SV (585 KB)
- Italian - IT (585 KB)
- Korean - KR (585 KB)
- Portuguese - PT (585 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kanzawa, F., et al., In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res, 2001. 7(1): p. 202-9. [Content Brief]
[2]. Uchida, N., et al., Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model. Eur J Cancer, 1998. 34(11): p. 1796-801. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 3.2984 mL | 16.4919 mL | 32.9837 mL | 82.4593 mL |
| 5 mM | 0.6597 mL | 3.2984 mL | 6.5967 mL | 16.4919 mL | |
| 10 mM | 0.3298 mL | 1.6492 mL | 3.2984 mL | 8.2459 mL | |
| 15 mM | 0.2199 mL | 1.0995 mL | 2.1989 mL | 5.4973 mL | |
| 20 mM | 0.1649 mL | 0.8246 mL | 1.6492 mL | 4.1230 mL | |
| 25 mM | 0.1319 mL | 0.6597 mL | 1.3193 mL | 3.2984 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz